# Ekalia Partners With Telix to Expand U.S. Radioisotope Production

- URL: https://stocks.freetheai.org/news/ekalia-partners-with-telix-to-expand-u-s-radioisotope-production-c9c3a4
- Published: 2026-10-19T05:30:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [ASX:TLX](https://stocks.freetheai.org/symbols/ASX-TLX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Ekalia, a joint venture formed by IBA and Framatome, has entered into an agreement to utilize the Radioisotope Logistics and Services network of Telix Pharmaceuticals Limited (ASX:TLX) to accelerate the rollout of its first U.S. Astatine-211 manufacturing facility. The initial production unit will be located in Trevose, Pennsylvania, with potential to expand across Telix's broader logistics footprint. Shares of Telix were down 2.10% at 15.4 AUD following the announcement.

As part of the agreement, Telix guarantees access to a portion of future Astatine-211 output. Astatine-211 is a crucial radioisotope used in targeted alpha therapies. Securing this supply de-risks potential bottlenecks in Telix's drug development pipeline and provides a scalable framework to distribute therapies across the United States as demand increases.

Investors will be watching for future operational updates, including formal commissioning milestones, target production start dates, regulatory approvals, and binding purchase agreements for the produced isotopes.

## Key points

- Ekalia will use the Telix Pharmaceuticals Limited (ASX:TLX) logistics network to launch its first U.S. Astatine-211 production unit in Trevose, Pennsylvania.
- Telix secures guaranteed access to a portion of future Astatine-211 supply to support its targeted alpha therapy pipeline.
- The partnership provides a scalable distribution footprint across the United States if production demand grows.
- Shares of Telix traded down 2.10% at 15.4 AUD following the announcement.

## Questions and answers

### What is the agreement between Ekalia and Telix Pharmaceuticals?

Ekalia will use the logistics network of Telix Pharmaceuticals Limited (ASX:TLX) to commission its first U.S. Astatine-211 manufacturing unit in Pennsylvania, giving Telix reserved access to future isotope supply.

### Where will the new Astatine-211 facility be located?

The initial production unit will be located at the Radioisotope Logistics and Services site in Trevose, Pennsylvania, with potential for further expansion.

### Why is Astatine-211 important for Telix Pharmaceuticals?

Astatine-211 is an essential isotope for targeted alpha therapies. Securing dedicated access helps reduce supply chain bottlenecks for Telix's therapeutic pipeline.